Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells

Bevacizumab (Bev) a humanized monoclonal antibody that fights vascular endothelial growth factor A (VEGF-A). It was the first specifically considered angiogenesis inhibitor and it has now become the normative first-line therapy for advanced non-small-cell lung cancer (NSCLC). In the current study, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanafy, Nemany A. N., Eltonouby, Eman Ali Bakr, Salim, Elsayed I., Mahfouz, Magdy E., Leporatti, Stefano, Hafez, Ezar H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963805/
https://www.ncbi.nlm.nih.gov/pubmed/36834960
http://dx.doi.org/10.3390/ijms24043548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963805/
https://www.ncbi.nlm.nih.gov/pubmed/36834960
http://dx.doi.org/10.3390/ijms24043548

Ejemplares similares